Recombinant Factor VIIa in Acute Intracerebral Haemorrhage - Full Text View

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

This study has been completed.

Sponsored by:	Novo Nordisk
Information provided by:	Novo Nordisk
ClinicalTrials.gov Identifier:	NCT00426803

Purpose

This trial is conducted in North America, Europe, Asia and Oceania.

The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

Condition	Intervention	Phase
Spontaneous Intracerebral Haemorrhage	Drug: Recombinant Factor VIIa	Phase II

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	Efficacy and Safety of Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Further study details as provided by Novo Nordisk:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	400
Study Start Date:	August 2002

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00426803

Sponsors and Collaborators

Novo Nordisk

More Information

Study ID Numbers:	F7ICH-1371
First Received:	January 24, 2007
Last Updated:	January 26, 2007
ClinicalTrials.gov Identifier:	NCT00426803
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Cerebral Hemorrhage

Vascular Diseases

Central Nervous System Diseases

Intracranial Hemorrhages

Brain Diseases

Hemorrhage

Cerebrovascular Disorders

Additional relevant MeSH terms:

Pathologic Processes

Nervous System Diseases

Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 05, 2008